Equities

Evofem Biosciences Inc

EVFM:QBB

Evofem Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.0095
  • Today's Change0.000 / -2.06%
  • Shares traded1.08m
  • 1 Year change-94.06%
  • Beta-0.7045
Data delayed at least 15 minutes, as of Sep 20 2024 20:50 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects Evofem Biosciences Inc share price to rise to 225.00 in the next year from the last price of 0.0095.
High2,368,321.1%225.00
Med2,368,321.1%225.00
Low2,368,321.1%225.00

Earnings history & estimates in USD

Earnings forecasts are not available for Evofem Biosciences Inc. On Aug 14, 2024, Evofem Biosciences Inc reported 2nd quarter 2024 losses of -- per share.
Evofem Biosciences Inc reported annual 2023 earnings of 0.05 per share on Mar 27, 2024.
Average growth rate+37.76%
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for Evofem Biosciences, Inc..
Evofem Biosciences, Inc. had revenues for the full year 2023 of 18.22m. This was 8.20% above the prior year's results.
Average growth rate+620.29%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.